NEW YORK (TheStreet) -- Shares of Isis Pharmaceuticals (ISIS) rose 3.1% to $61.51 in early market trading Tuesday after chairman and CEO Dr. Stanley Crooke appeared on Jim Cramer's Mad Money show on CNBC on Monday.
Crooke discussed Monday's news that Isis had entered into a licensing deal with Bayer (BAYRY) to for its blood-thinning drug currently named Factor 11, or FRXI. The drug is expected to be a significant blockbuster.
The CEO said Isis explored partnerships with many companies but Bayer knows the industry well and has both the experience and the dedication to make Factor 11 a successful product.
Crooke said Isis would discuss the deal further during its earnings call on Tuesday. He added that Isis would update shareholders on its muscular dystrophy and diabetes trials and would also have an update on Akcea Therapeutics, the new Isis subsidiary that will develop lipid drugs.
Isis is up more than 350% since Cramer first got behind the stock in October 2012.
Separately, TheStreet Ratings team rates ISIS PHARMACEUTICALS INC as a Hold with a ratings score of C. TheStreet Ratings Team has this to say about their recommendation:
"We rate ISIS PHARMACEUTICALS INC (ISIS) a HOLD. The primary factors that have impacted our rating are mixed, some indicating strength, some showing weaknesses, with little evidence to justify the expectation of either a positive or negative performance for this stock relative to most other stocks. The company's strengths can be seen in multiple areas, such as its robust revenue growth, solid stock price performance and compelling growth in net income. However, as a counter to these strengths, we also find weaknesses including generally higher debt management risk and poor profit margins."